

SPARC/Sec/SE/2020-21/038

2nd December 2020

To
BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: Disclosure of Related Party Transactions – September 2020

Dear Sir/ Madam,

In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended September 30, 2020.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sun Pharma Advanced Research Company Limited

Debashis Dey
Company Secretary

Encl: As above.

Indian Accounting Standard (Ind AS-24) " Related Party Disclosures "

Names of related parties and description of relationship

1. Key Management Personnel

Dilip S. Shanghvi	Chairman & Managing Director
Sudhir V. Valia	Non Executive Director
Rajamannar Tennati	Non-Executive Director
Bhavna Doshi	Independent Director
Ferzaan Engineer	Independent Director
Robert Jay Spiegel	Independent Director (w.e.f. 1st June 2020)

2. Holding Company

Shanghvi Finance Private Limited

3. Enterprise under Significant Influence of Key Management Personnel (with whom transactions are entered during the half year ended September 30, 2020)

Sun Pharma Global FZE

Sun Pharma Laboratories Limited

Sun Pharmaceutical Industries Europe BV

Sun Pharmaceutical Industries Inc.

Sun Pharmaceutical Industries Limited

Taro Pharmaceuticals Industries Limited

₹ In Lakhs

Particulars	Half Year ended September 30, 2020
Director Sitting Fees	
Sudhir V. Valia	3.30
Rajamannar Tennati	1.50
Bhavna Doshi	3.60
Ferzaan Engineer	3.30
Robert Jay Spiegel	3.00
Shanghvi Finance Private Limited	
Loan received	12,500.00
Loan repayment	8,500.00
Interest paid	279.33
Sun Pharma Global FZE	
Sale of services - License fees / Royalty	45.56
Sale of services - R&D services	333.96
Sun Pharma Laboratories Limited	
Sale of services - License fees / Royalty	2,751.62
Sale of services - R&D services	34.93
Purchase of goods	0.15
Sun Pharmaceutical Industries Europe BV	
Purchase of goods	1.23
Sun Pharmaceutical Industries Inc.	
Sale of services - R&D services	6.55
Purchase of Services - R&D services	997.85
Reimbursement of expenses paid	680.43
Purchase of goods	25.01
Sun Pharmaceutical Industries Limited	
Sale of services - License fees / Royalty	16,603.03
Sale of services - R&D services	532.82
Purchase of goods	76.38
Purchase of property, plant & equipment	14.56
Rent expenses	101.78
Purchase of Services - R&D services	366.22
Reimbursement of expenses paid	441.13
Reimbursement of expenses received	8.47
Taro Pharmaceuticals Industries Limited	
Sale of services - R&D services	0.80

SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

Balance outstanding - Receivable / (Payable)

₹ In Lakhs

Particulars	As at September 30, 2020
Sun Pharma Global FZE	230.53
Sun Pharma Laboratories Limited	940.19
Sun Pharmaceutical Industries Europe BV	(5.21)
Sun Pharmaceutical Industries Inc.	(4,070.36)
Sun Pharmaceutical Industries Limited	(439.83)
Taro Pharmaceuticals Industries Limited	0.47
Shanghvi Finance Private Limited	(10,092.47)
Insite Vision	(0.96)

Chetan M. Rajpara
Chief Financial Officer